Adjuvant Trastuzumab did not improve outcomes for patients with HER2-low breast cancer
Adding trastuzumab (Herceptin) to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, as defined as immunohistochemistry ...
Dec 6, 2017